Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: A FRISC II substudy: reply  by Lindahl, Bertil
merely the troponin elevation, but rather the etiology behind
the elevation, that makes the most difference clinically.
Francis Q. Almeda, MD
Section of Cardiology
Rush-Presbyterian–St. Luke’s Medical Center
1021 Jelke
1653 West Congress Parkway
Chicago, Illinois 60612
E-mail: Francis_Q_Almeda@rush.edu
James E. Calvin, MD
PII S0735-1097(02)01762-X
REFERENCES
1. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L, and the
FRISC II Investigators. Mechanisms behind the prognostic value of
troponin T in unstable coronary artery disease: a FRISC II substudy.
J Am Coll Cardiol 2001;38:979–86.
2. Almeda FQ, Calvin JE, Parrillo JE, Sun FG, Barron JT. Prevalence of
angiographically significant stenosis in patients with chest pain and an
elevated troponin I level and normal creatine kinase and creatine
kinase-MB levels. Am J Cardiol 2001;87:1286–9.
3. Casas RE, Marriott HJ, Glancy DL. Value of leads V7–V9 in diagnos-
ing posterior wall acute myocardial infarction and other causes of tall R
waves in V1–V2. Am J Cardiol 1997;80:508–9.
4. Agarwal JB, Khaw K, Aurignac F, Locurto A. Importance of posterior
chest leads in patients with suspected myocardial infarction, but
nondiagnostic, routine 12-lead electrocardiogram. Am J Cardiol 1999;
83:323–6.
5. Robalino BD, Whitlow PL, Underwood DA, Salcedo EE. Electrocar-
diographic manifestations of right ventricular infarction. Am Heart J
1989;118:138–44.
6. Antman EM. Troponin measurements in ischemic heart disease: more
than just a black and white picture. J Am Coll Cardiol 2001;38:987–90.
REPLY
We do appreciate the valuable comments from Drs. Almeda and
Calvin regarding our article (1) and are happy to provide, as a
response to their questions, some further data from the FRISC II
study. Drs. Almeda and Calvin wonder how often electrocardio-
gram (ECG) changes suggestive of posterior wall injury (i.e.,
ST-segment depression in the anterior precordial leads) were
present on admission in patients with occlusion of the left
circumflex artery as the culprit lesion. Unfortunately, the database
did not contain information about ST-segment depression in each
of the 12 individual leads, but only whether ST-segment depres-
sion was present in anterior, lateral or inferior leads. However, in
patients with occlusion of the left circumflex artery as the culprit
lesion, ST-segment depression was located exclusively in the
anterior leads in only 5% (4/75). The ST-segment depression in
the anterior leads together with ST-segment depression in the
lateral or inferior leads was present in 13% (10/75) of patients.
Thus, as pointed out by Drs. Almeda and Calvin, to be able to
rapidly identify patients with occlusion of the left circumflex artery
we need better diagnostic techniques than the standard 12-lead
ECG.
Drs. Almeda and Calvin also ask about the outcome in patients
with “normal” (50% stenosis) coronary arteries and an elevated
troponin T level (tnT). In the invasive cohort, 57 patients had
“normal” coronary arteries and an elevated tnT; the median tnT
level among those was 0.23 g/l (10th to 90th percentile, 0.02 to
0.73). Among those 57 patients, 2 patients (3.5%) suffered a
myocardial infarction (MI) and none died during the one-year
follow-up. Thus, this was much lower than the event rates
(approximately 17% MI and 4% death) seen in the patients with
corresponding tnT levels (the two middle quartiles, tnT 0.01 to
0.63 g/l) in the noninvasive cohort. In fact, the event rates among
those with “normal” coronary arteries and an elevated tnT were not
significantly different from those seen in the 101 patients with
“normal” coronary arteries and no tnT elevation (one MI and no
deaths). These data further support the important point that Drs.
Almeda and Calvin make, namely that “troponin elevations are, in
and of itself, not equivalent, and that it is not merely the troponin
elevation, but rather the etiology behind the elevation, that makes
the most difference clinically.”
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Late-Onset Primary LVH:
HCM Versus Cardiac Fabry Variant
In their article that appeared in the August 2001 issue of JACC,
Maron et al. (1) suggest that left ventricular hypertrophy (LVH)
can be a late manifestation of hypertrophic cardiomyopathy
(HCM) due to cardiac myosin-binding protein C (MyBP-C)
mutations. However, the echocardiographically documented LVH
developing in their midlife in patients with MyBP-C mutations
cannot be attributed for certain to that genetic abnormality unless
a histologic demonstration of HCM can be provided by LV
endomyocardial biopsy.
In fact, penetrance of MyBP-C mutations in large series ranges
between 37% and 71% even in patients over 50 years of age (2–4),
and other genetic disorders that give rise to LVH in middle-aged
patients also exist, such as the cardiac variant of Fabry disease (5,6).
This last entity, although X-linked, can occur in both male and
female patients (7), can account for up to 9% of patients with
nonobstructive HCM (8,9) and can be diagnosed simply by
assessment of the alpha-galactosidase A enzymatic activity in the
peripheral blood. If Fabry disease was present even in a proportion
of patients with presumed HCM, those patients could now benefit
from galactose infusion (10) and/or enzyme replacement therapy
(11).
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